Clinical study on the tolerance of cefazedone.
Tolerance of (6R,7R)-7-(2-[3,5-dichloro-4-oxo-1(4H)-pyridyl]-acetamido)-3-([(5-methyl-1,3,4-thiadiazol-2-yl)-thio]methyl)-8-oxo-5-thia-1-azabicyclo[4,2,0]oct-2-ene-2-carboxylic acid (cefazedone, Refosporen) (3X1 g or 3X2 g/day; dosage interval 8 hours; duration of treatment 1 week) was examined in i.v. administration to 20 patients using numerous parameters. In 2 patients treatment was stopped sooner on account of the development of a morbilliform rash; a causal relation between this and the chemotherapy seemed probable in one case and possible in the other. 1 patient developed a transitory thrombocytosis without clinical symptoms, in 2 female patients yeasts were found in the mid-stream urine. Changes in the red or white blood count, in serum electrolytes, in bilirubin or increases in the activity of serum enzymes were not found. Indications of disturbances in renal function could be ruled out by examinations of endogenous creatinine clearance; repeat analyses of excretion of erythrocytes, nucleated cells and various urinary enzymes did not provide any indication of even slight renal lesions. Local tolerance of the substance was good.
D000328:Adult; D000368:Aged; D001769:Blood / Q000187:drug effects; D002511:Cephalosporins / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D005260:Female; D006801:Humans; D007275:Injections, Intravenous; D008297:Male; D008875:Middle Aged; D014556:Urine / Q000187:drug effects
D002511:Cephalosporins